{"id":"tetraxetan","rwe":[{"pmid":"41746558","year":"2026","title":"Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.","finding":"","journal":"EJNMMI radiopharmacy and chemistry","studyType":"Clinical Study"},{"pmid":"41741857","year":"2026","title":"Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective.","finding":"","journal":"AAPS PharmSciTech","studyType":"Clinical Study"},{"pmid":"41623163","year":"2026","title":"Site-Specific Asymmetric Coordination Engineering in Defective Metal-Organic Frameworks Stabilizes Cu(I) Active Sites for Selective CO(2)-to-Methanol Photocatalysis.","finding":"","journal":"Journal of the American Chemical Society","studyType":"Clinical Study"},{"pmid":"41598623","year":"2026","title":"Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium ((177)Lu)Vipivotide Tetraxetan, and Abiraterone.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41595153","year":"2026","title":"PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions.","finding":"","journal":"Cancers","studyType":"Clinical Study"}],"_fda":{"id":"4d7d1071-153c-4073-9a10-1a4185778dfe","set_id":"14908037-2892-4d98-a053-253ce35afb1a","openfda":{"nui":["N0000194017","N0000194016"],"unii":["G6UF363ECX"],"route":["INTRAVENOUS"],"rxcui":["2597057","2597060"],"spl_id":["4d7d1071-153c-4073-9a10-1a4185778dfe"],"brand_name":["PLUVICTO"],"spl_set_id":["14908037-2892-4d98-a053-253ce35afb1a"],"package_ndc":["0078-1217-61"],"product_ndc":["0078-1217"],"generic_name":["LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN"],"pharm_class_epc":["Radioligand Therapeutic Agent [EPC]"],"pharm_class_moa":["Radioligand Activity [MoA]"],"manufacturer_name":["Novartis Pharmaceuticals Corporation"],"application_number":["NDA215833"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)] . There are no available data on PLUVICTO use in pregnant females. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radioactive emissions, including those from PLUVICTO, can cause fetal harm."],"overdosage":["10 OVERDOSAGE In the event of administration of a radiation overdosage with PLUVICTO, reduce the radiation absorbed dose to the patient by increasing the elimination of the radionuclide from the body by frequent micturition or by forced diuresis and frequent bladder voiding. Estimate the effective radiation dose that was applied and treat with additional supportive care measures as clinically indicated."],"description":["11 DESCRIPTION PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177. The chemical name is 2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxy propyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate; lutetium-177(3+). The molecular mass is 1216.06 g/mol and the molecular formula is C 49 H 68 177 LuN 9 O 16 . The chemical structure for lutetium Lu 177 vipivotide tetraxetan is shown below: PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) 1,000 MBq/mL (27 mCi/mL) Injection is supplied as a sterile, clear, colorless to slightly yellow solution for intravenous use. Each single-dose vial contains acetic acid (0.30 mg/mL), sodium acetate (0.41 mg/mL), gentisic acid (0.39 mg/mL), sodium ascorbate (50.0 mg/mL), pentetic acid (0.10 mg/mL), and water for injection (q.s. to 1 mL). The pH range of the solution is 4.5 to 7.0. Chemical Structure of lutetium 11.1 Physical Characteristics Lutetium-177 decays to a stable hafnium-177 with a physical half-life of 6.647 days by emitting beta-minus radiation with a maximum energy of 498 keV (79%) and photonic radiation (γ) of 208 keV (11%) and 113 keV (6.4%). The main radiations of lutetium-177 are detailed in Table 7. Table 7: Lutetium-177 Main Radiations Radiation Energy (keV) Iβ - % Iγ% β - 176.5 12.2 β - 248.1 0.05 β - 384.9 9.1 β - 497.8 78.6 γ 71.6 0.15 γ 112.9 6.40 γ 136.7 0.05 γ 208.4 11.0 γ 249.7 0.21 γ 321.3 0.22 11.2 External Radiation Table 8 summarizes the radioactive decay properties of lutetium-177. Table 8: Physical Decay Chart: Lutetium-177 Physical Half-life = 6.647 days Hours Fraction remaining 0 1.000 1 0.996 2 0.991 5 0.979 10 0.958 24 (1 day) 0.901 48 (2 days) 0.812 72 (3 days) 0.731 120 (5 days) 0.594 168 (7 days) 0.482 336 (14 days) 0.232 720 (30 days) 0.044 1080 (45 days) 0.009"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING PLUVICTO Injection containing 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan is a sterile, preservative-free and clear, colorless to slightly yellow solution for intravenous use supplied in a clear, colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 vipivotide tetraxetan at the date and time of administration (NDC# 0078-1217-61). The solution volume in the vial can range from 7.5 mL to 12.5 mL in order to provide a total of 7.4 GBq (200 mCi) of radioactivity at the date and time of administration. The product vial is enclosed within a lead shielded container (NDC# 0078-1217-61) for protective shielding and placed in a plastic sealed container. The product is shipped in a type A package. The shelf life is 120 hours (5 days) from the date and time of calibration. Store below 30°C (86°F). Do not freeze. Store in the original package to protect from ionizing radiation (lead shielding). Store PLUVICTO in accordance with local and federal laws on radioactive materials. Do not use PLUVICTO after the expiration date and time which are stated on the label. Dispose of any unused medicinal product or waste material in accordance with local and federal laws. Lutetium-177 for PLUVICTO may be prepared using two different sources of stable nuclides (either lutetium-176 or ytterbium-176) that require different waste management. Lutetium-177 for PLUVICTO is prepared using ytterbium-176 (“non-carrier added”) unless otherwise communicated on the product batch release certificate."],"geriatric_use":["8.5 Geriatric Use Of the 227 patients who received at least one dose of PLUVICTO in the PSMAfore study, 177 patients (78%) were 65 years of age or older and 83 patients (37%) were 75 years of age or older. No overall differences in effectiveness were observed between patients ≥ 75 years of age and younger patients. Serious adverse reactions occurred in 20% of patients ≥ 75 years of age and in 20% of younger patients. Grade ≥ 3 adverse reactions occurred in 39% of patients ≥ 75 years of age and in 34% of younger patients. Of the 529 patients who received at least one dose of PLUVICTO plus BSoC in the VISION study, 387 patients (73%) were 65 years of age or older and 143 patients (27%) were 75 years of age or older. No overall differences in effectiveness were observed between patients ≥ 75 years of age and younger patients. Serious adverse reactions occurred in 41% of patients ≥ 75 years of age and in 35% of younger patients. Grade ≥ 3 adverse reactions occurred in 56% of patients ≥ 75 years of age and in 53% of younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of PLUVICTO in pediatric patients have not been established."],"effective_time":"20260407","clinical_studies":["14 CLINICAL STUDIES 14.1 PSMA-Positive mCRPC Previously Treated With ARPI Therapy PSMAfore The efficacy of PLUVICTO was evaluated in PSMAfore (NCT04689828), a randomized (1:1), multicenter, open-label trial that evaluated PLUVICTO (N = 234) versus a change in ARPI (N = 234) in patients with progressive, PSMA-positive mCRPC. Randomization was stratified by setting of prior ARPI use [castration-resistant prostate cancer (CRPC) vs. hormone-sensitive prostate cancer (HSPC)] and by symptomatology [asymptomatic or mildly symptomatic vs. symptomatic]. Patients were required to have a castrate level of serum/plasma testosterone by either medical castration or prior orchiectomy at study entry. Patients were required to have progressed only once on an ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide). Prior taxane-based chemotherapy was only allowed in the adjuvant or neoadjuvant setting greater than 12 months before enrollment. Patients were considered appropriate for delay of taxane-based chemotherapy by the investigator. Patients were required to have PSMA-positive mCRPC defined as having at least one tumor lesion (soft tissue or bone) with gallium Ga 68 gozetotide uptake greater than in normal liver. Patients were considered ineligible if any intraprostatic lesion or any one lesion larger than size criteria [organs ≥ 1 cm in longest diameter, lymph nodes ≥ 2.5 cm in short axis, bones (soft tissue component) ≥ 1 cm in longest diameter] had gallium Ga 68 gozetotide uptake less than or equal to uptake in normal liver. Patients received PLUVICTO 7.4 GBq (200 mCi) every 6 weeks for 6 doses or a change in ARPI. Supportive care administered at the investigator’s discretion included bone-targeted agents; androgen deprivation therapy (ADT); or palliative radiotherapy. The median age was 72 years (range, 43 to 94 years); 91% were White; 2.6% Black or African American; 0.6% Asian; 6% were Hispanic or Latino; 99% had ECOG PS0-1. The major efficacy outcome measure was radiographic progression-free survival (rPFS) as determined by blinded independent central review (BICR) per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Additional efficacy outcome measures were Overall Survival (OS) and Overall Response Rate (ORR). PSMAfore demonstrated a statistically significant improvement in rPFS for PLUVICTO compared to a change in ARPI. Of patients that were randomized to receive a change in ARPI, 141 patients (60%) crossed over to receive PLUVICTO after confirmation of radiographic disease progression by BICR. Efficacy results for PSMAfore are presented in Table 9 and Figure 1. Table 9: Efficacy Results in PSMAfore ARPI = androgen receptor pathway inhibitor; NE = Not estimable; NS = Not statistically significant a By BICR per PCWG3-modified RECIST v1.1 criteria. b Excludes one patient in the PLUVICTO arm who was randomized after the data cut-off for the rPFS primary analysis. c Based on Kaplan-Meier estimate. d Hazard ratio based on the stratified Cox PH model. e Stratified log-rank test one-sided p-value. f Responses are based on soft tissue and bone lesion assessment. PLUVICTO ARPI Radiographic progression-free survival (rPFS) a N = 233 b N = 234 Events (progression or death), n (%) 60 (26) 106 (45) Median, months (95% CI) c 9.3 (7, NE) 5.6 (4, 6) Hazard ratio (95% CI) d 0.41 (0.29, 0.56) P-value e < 0.0001 Overall survival (OS) N = 234 N = 234 Deaths, n (%) 142 (61) 157 (67) Median, months (95% CI) c 24.5 (19.5, 28.9) 23.1 (19.6, 25.5) Hazard ratio (95% CI) d 0.91 (0.72, 1.14) P-value e NS Overall response rate (ORR) a,f Patients with measurable disease at baseline N = 72 N = 72 ORR (CR + PR), n (%) (95% CI) 35 (49) (37, 61) 10 (14) (7, 24) Complete response (CR), n (%) 15 (21) 2 (2.8) Partial response (PR), n (%) 20 (28) 8 (11) Figure 1. Kaplan-Meier Plot of Radiographic Progression-Free Survival in PSMAfore Figure 1. Kaplan-Meier Plot of Radiographic Progression-Free Survival in PSMAfore 14.2 PSMA-Positive mCRPC Previously Treated With ARPI Therapy and Taxane-Based Chemotherapy VISION The efficacy of PLUVICTO was evaluated in VISION (NCT03511664), a randomized (2:1), multicenter, open-label trial of PLUVICTO plus BSoC (N = 551) versus BSoC alone (N = 280) in patients with progressive, PSMA-positive mCRPC. Randomization was stratified by baseline lactase dehydrogenase (LDH ≤ 260 IU/L vs. > 260 IU/L), presence of liver metastases (yes vs. no), ECOG PS score (0 or 1 vs. 2), and inclusion of an AR pathway inhibitor as part of BSoC (yes vs. no) at the time of randomization. Patients were required to have a castrate level of serum/plasma testosterone by either medical castration or prior orchiectomy at study entry. Patients were required to have received at least one ARPI, and 1 or 2 prior taxane-based chemotherapy regimens. Eligible patients were required to have PSMA-positive mCRPC defined as having at least one tumor lesion (soft tissue or bone) with gallium Ga 68 gozetotide uptake greater than in normal liver. Patients were considered ineligible if any one lesion larger than size criteria [organs ≥ 1 cm in short axis, lymph nodes ≥ 2.5 cm in short axis, bones (soft tissue component) ≥ 1 cm in short axis] had gallium Ga 68 gozetotide uptake less than or equal to uptake in normal liver. Patients received PLUVICTO 7.4 GBq (200 mCi) every 6 weeks for up to a total of 6 doses plus BSoC or BSoC alone. BSoC administered at the investigator’s discretion included ketoconazole; radiation therapy to localized prostate cancer targets; bone-targeted agents; ADT; ARPIs. Patients continued treatment for up to 4-6 doses, or until disease progression or unacceptable toxicity. Patients with stable disease or partial response after 4 doses of PLUVICTO plus BSoC received up to 2 additional doses per investigator’s discretion. The median age was 71 years (range, 40 to 94 years); 87% White; 7% Black or African American; 2.4% Asian; 1.7% were Hispanic or Latino; 92% had ECOG PS0-1; 8% had ECOG PS2. All patients had received at least one prior taxane-based chemotherapy regimen and 41% of patients received two. One prior ARPI had been administered to 51% of patients, 41% of patients had received 2, and 8% of patients had received 3 or more. During the treatment period, 53% of patients in the PLUVICTO plus BSoC arm and 68% of patients in the BSoC alone arm received at least one ARPI. The major efficacy outcome measures were OS and rPFS as determined by BICR per PCWG3-modified RECIST v1.1 criteria. An additional efficacy outcome measure was ORR. VISION demonstrated a statistically significant improvement in both major efficacy outcome measures of OS and rPFS by BICR with PLUVICTO plus BSoC compared to treatment with BSoC alone. Interpretation of the magnitude of the rPFS effect was limited due to a high degree of censoring from early drop out in the control arm. Efficacy results for VISION are presented in Table 10 and Figure 2. Table 10: Efficacy Results in VISION a Based on Kaplan-Meier estimate. b Hazard ratio based on the stratified Cox PH model. c Stratified log-rank test two-sided p-value. d Responses are based on soft tissue and bone lesion assessment. e By BICR per PCWG3-modified RECIST v1.1 criteria. f Stratified Wald’s Chi-square test two-sided p-value. PLUVICTO plus BSoC BSoC Overall survival (OS) N = 551 N = 280 Deaths, n (%) 343 (62) 187 (67) Median, months (95% CI) a 15.3 (14.2, 16.9) 11.3 (9.8, 13.5) Hazard ratio (95% CI) b 0.62 (0.52, 0.74) P-value c < 0.001 Overall response rate (ORR) d,e Patients with measurable disease at baseline N = 184 N = 64 ORR (CR + PR), n (%) (95% CI) 91 (49) (42, 57) 1 (1.6) (0, 8) Complete response (CR), n (%) 17 (9) 0 (0) Partial response (PR), n (%) 74 (40) 1 (1.6) P-value f < 0.001 Figure 2. Kaplan-Meier Plot of Overall Survival in VISION Figure 2. Kaplan-Meier Plot of Overall Survival in VISION"],"pharmacodynamics":["12.2 Pharmacodynamics Lutetium Lu 177 vipivotide tetraxetan exposure-efficacy relationships and the time course of pharmacodynamic response have not been fully characterized. Cardiac Electrophysiology At the recommended dosage, PLUVICTO does not cause large mean increases (> 20 ms) in the QTc interval."],"pharmacokinetics":["12.3 Pharmacokinetics Pharmacokinetics of lutetium Lu 177 vipivotide tetraxetan are expressed as geometric mean (geometric mean coefficient of variation) unless otherwise specified. The blood lutetium Lu 177 vipivotide tetraxetan area under the curve (AUC) is 52.3 ng.h/mL (31.4%) and the maximum blood concentration (C max ) is 6.58 ng/mL (43.5%) at the recommended dosage. Distribution Lutetium Lu 177 vipivotide tetraxetan volume of distribution is 123 L (78.1%). Within 2.5 hours after administration, lutetium Lu 177 vipivotide tetraxetan distributes in gastrointestinal tract, liver, lungs, kidneys, heart wall, bone marrow, and salivary glands. Vipivotide tetraxetan and non-radioactive lutetium vipivotide tetraxetan are 60% to 70% bound to human plasma proteins. Elimination The lutetium Lu 177 vipivotide tetraxetan terminal elimination half-life is 41.6 hours (68.8%) and the clearance (CL) is 2.04 L/h (31.5%). Metabolism Lutetium Lu 177 vipivotide tetraxetan does not undergo hepatic or renal metabolism. Excretion Lutetium Lu 177 vipivotide tetraxetan is primarily eliminated renally. Specific Populations Exposure (AUC) of lutetium Lu 177 vipivotide tetraxetan increased with decreasing creatinine clearance (CLcr). The effect of baseline CLcr < 54 mL/min on lutetium Lu 177 vipivotide tetraxetan pharmacokinetics has not been studied. Drug Interaction Studies In Vitro Studies CYP450 enzymes: Vipivotide tetraxetan is not a substrate of cytochrome P450 (CYP450) enzymes. Vipivotide tetraxetan did not induce CYP1A2, 2B6 or 3A4; and did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A in vitro. Transporters: Vipivotide tetraxetan is not a substrate of BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3 or OCT2. Vipivotide tetraxetan did not inhibit BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 or OCT2 in vitro."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions (5.2)] Renal Toxicity [see Warnings and Precautions (5.3)] Most common (≥ 20%) adverse reactions, including laboratory abnormalities, were decreased lymphocytes, decreased hemoglobin, fatigue, dry mouth, decreased platelets, decreased estimated glomerular filtration rate, nausea, decreased neutrophils, decreased calcium, decreased sodium, increased aspartate aminotransferase, increased alkaline phosphatase, arthralgia, decreased appetite, increased potassium, constipation, and back pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the pooled safety population for the PSMAfore and VISION studies (N = 756), the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were decreased lymphocytes (83%), decreased hemoglobin (65%), fatigue (49%), dry mouth (46%), decreased platelets (40%), decreased estimated glomerular filtration rate (37%), nausea (35%), decreased neutrophils (31%), decreased calcium (29%), decreased sodium (27%), increased aspartate aminotransferase (26%), increased alkaline phosphatase (24%), arthralgia (22%), decreased appetite (21%), increased potassium (21%), constipation (21%), and back pain (21%). PSMAfore The safety of PLUVICTO was evaluated in the PSMAfore study in patients with progressive, PSMA-positive mCRPC previously treated with ARPI therapy, for whom it was considered appropriate to delay taxane-based chemotherapy by the investigator [see Clinical Studies (14.1)] . Patients received at least one dose of either PLUVICTO 7.4 GBq (200 mCi) administered every 6 weeks (N = 227) or a change in ARPI (N = 232). The median duration of exposure to PLUVICTO was 8.4 months (range, 0.4 to 11.6), and the median number of doses of PLUVICTO received was 6 (range, 1 to 6). The median cumulative administered activity of PLUVICTO was 42.4 GBq (range, 7.0 to 45.4). Serious adverse reactions occurred in 20% of patients who received PLUVICTO. Serious adverse reactions in > 1% of patients who received PLUVICTO included anemia (1.8%), urinary tract infection (1.8%), hemorrhage (1.3%), and sepsis (1.3%). Fatal adverse reactions occurred in 1.8% of patients who received PLUVICTO, including COVID-19 pneumonia, cardiac arrest, intestinal ischemia, and sepsis (0.4% each). PLUVICTO was permanently discontinued due to adverse reactions in 6% of patients. Adverse reactions leading to permanent discontinuation of PLUVICTO in ≥ 1% of patients who received PLUVICTO were thrombocytopenia (1.8%) and dry mouth (1.3%). Adverse reactions leading to a dose interruption of PLUVICTO occurred in 12% of patients. The most frequent (≥ 1%) adverse reactions leading to a dose interruption of PLUVICTO in patients who received PLUVICTO were COVID-19 (3.1%) and anemia (1.8%). Adverse reactions leading to a dose reduction of PLUVICTO occurred in 3.5% of patients. The most frequent (≥ 0.5%) adverse reaction leading to a dose reduction of PLUVICTO in patients who received PLUVICTO was dry mouth (0.9%). Table 3 and Table 4 summarize the incidence of adverse reactions and laboratory abnormalities, respectively, in PSMAfore. Table 3: Adverse Reactions (≥ 10%) in Patients With PSMA-Positive mCRPC Who Received PLUVICTO in PSMAfore Abbreviation: ARPI, androgen receptor pathway inhibitor. a Includes multiple similar terms. Adverse reactions PLUVICTO (N = 227) ARPI (N = 232) All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Gastrointestinal disorders Dry mouth a 61 0.9 2.6 0 Nausea 32 0 12 0.4 Constipation 22 0.4 14 0 Diarrhea 17 0 9 0.4 Vomiting 11 0 4.7 0 General disorders Fatigue a 53 1.3 53 5 Metabolism and nutrition disorders Decreased appetite 22 0 19 0.4 Musculoskeletal and connective tissue disorders Arthralgia 20 0 23 0.4 Back pain 14 1.3 20 2.6 Clinically relevant adverse reactions in < 10% of patients who received PLUVICTO included dysgeusia, abdominal pain, peripheral edema, headache, acute kidney injury, weight decreased, urinary tract infection, dry eye, dizziness, dry skin, oral fungal infection, gastroesophageal reflux disease, pyrexia, vertigo, stomatitis, dysphagia, esophagitis, pancytopenia, and bone marrow failure. Table 4: Select Laboratory Abnormalities (≥ 10%) That Worsened From Baseline in Patients With PSMA-Positive mCRPC Who Received PLUVICTO or Change in ARPI (Between Arm Difference of ≥ 5% All Grades) in PSMAfore Abbreviation: ARPI, androgen receptor pathway inhibitor. a The denominator used to calculate the rate for each laboratory parameter was based on 226 patients with a baseline value and at least one post-treatment value. b The denominator used to calculate the rate for each laboratory parameter varied from 231 to 232 based on the number of patients with a baseline value and at least one post-treatment value. c No Grade 4 laboratory abnormalities worsening from baseline were reported. Laboratory abnormalities PLUVICTO a ARPI b All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Hematology Decreased lymphocytes 78 27 57 12 Decreased hemoglobin 67 7 c 50 7 c Decreased neutrophils 38 3.5 18 1.3 Decreased platelets 30 2.7 11 1.7 Chemistry Increased alkaline phosphatase 31 8 50 10 c Decreased estimated glomerular filtration rate (eGFR) 23 0.9 c 22 3.5 Increased magnesium 19 0.9 c 28 0 c Decreased calcium 18 0.9 11 0.9 Decreased sodium 11 0 c 18 0 c Decreased potassium 6 0.9 c 18 2.6 VISION The safety of PLUVICTO was evaluated in the VISION study in patients with progressive, PSMA-positive mCRPC previously treated with ARPI therapy and taxane-based chemotherapy [see Clinical Studies (14.2)] . Patients received at least one dose of either PLUVICTO 7.4 GBq (200 mCi) administered every 6 weeks plus BSoC (N = 529) or BSoC alone (N = 205). The median duration of exposure to PLUVICTO plus BSoC was 7.8 months (range, 0.3 to 36.5). Among patients who received PLUVICTO plus BSoC, the median number of doses of PLUVICTO received was 5 (range, 1 to 6). The median cumulative administered activity of PLUVICTO was 37.5 GBq (range, 7.0 to 48.3). Serious adverse reactions occurred in 37% of patients who received PLUVICTO plus BSoC. Serious adverse reactions in > 1% of patients who received PLUVICTO plus BSoC included musculoskeletal pain (4%), hemorrhage (4%), sepsis (3.2%), urinary tract infection (3%), anemia (2.8%), acute kidney injury (1.9%), pneumonia (1.7%), pyrexia (1.5%), pancytopenia (1.3%), spinal cord compression (1.1%), and pulmonary embolism (1.1%). Fatal adverse reactions occurred in 3% of patients who received PLUVICTO plus BSoC, including sepsis (0.9%), pancytopenia (0.6%), hepatic failure (0.4%), intracranial hemorrhage (0.2%), subdural hematoma (0.2%), ischemic stroke (0.2%), COVID-19 (0.2%), and aspiration pneumonia (0.2%). PLUVICTO was permanently discontinued due to adverse reactions in 12% of patients. Adverse reactions leading to permanent discontinuation of PLUVICTO in ≥ 1% of patients who received PLUVICTO plus BSoC were anemia (2.8%), thrombocytopenia (2.8%), and leukopenia (including neutropenia) (1.7%). Adverse reactions leading to a dose interruption of PLUVICTO occurred in 16% of patients. The most frequent (≥ 3%) adverse reactions leading to a dose interruption of PLUVICTO in patients who received PLUVICTO plus BSoC were anemia (5%) and thrombocytopenia (3.6%). Adverse reactions leading to a dose reduction of PLUVICTO occurred in 6% of patients. The most frequent (≥ 1%) adverse reactions leading to a dose reduction of PLUVICTO in patients who received PLUVICTO plus BSoC were thrombocytopenia (1.9%) and anemia (1.3%). Table 5 and Table 6 summarize the incidence of adverse reactions and laboratory abnormalities, respectively, in VISION. Table 5: Adverse Reactions (≥ 10%) in Patients With PSMA-Positive mCRPC Who Received PLUVICTO Plus BSoC in VISION Abbreviation: BSoC, best standard of care. a Includes multiple similar terms. Adverse reactions PLUVICTO plus BSoC (N = 529) BSoC (N = 205) All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) General disorders Fatigue a 48 7 29 2.4 Decreased appetite 21 1.9 15 0.5 Weight decreased 11 0.4 10 0.5 Peripheral edema a 10 0.4 7 1 Gastrointestinal disorders Dry mouth a 39 0 1 0 Nausea 36 1.3 17 0.5 Constipation 20 1.1 11 0.5 Vomiting a 19 0.9 6 0.5 Diarrhea 19 0.8 2.9 0.5 Abdominal pain a 12 1.3 6 0.5 Musculoskeletal and connective tissue disorders Back pain 24 3.6 15 3.9 Arthralgia 22 1.1 13 0.5 Bone pain 11 2.5 8 2.4 Renal and urinary disorders Urinary tract infection a 12 3.8 1 0.5 Clinically relevant adverse reactions in < 10% of patients who received PLUVICTO plus BSoC included acute kidney injury, dizziness, dysgeusia, headache, pyrexia, dry eye, oral fungal infection, vertigo, gastroesophageal reflux disease, stomatitis, pancytopenia, dry skin, dysphagia, esophagitis, and bone marrow failure. Table 6: Select Laboratory Abnormalities (≥ 10%) That Worsened From Baseline in Patients With PSMA-Positive mCRPC Who Received PLUVICTO Plus BSoC (Between Arm Difference of ≥ 5% All Grades) in VISION Abbreviation: BSoC, best standard of care. a The denominator used to calculate the rate for each laboratory parameter varied from 506 to 529 based on the number of patients with a baseline value and at least one post-treatment value. b The denominator used to calculate the rate for each laboratory parameter varied from 194 to 198 based on the number of patients with a baseline value and at least one post-treatment value. c No Grade 4 laboratory abnormalities worsening from baseline were reported. Laboratory abnormalities PLUVICTO plus BSoC a BSoC b All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Hematology Decreased lymphocytes 85 47 51 18 Decreased hemoglobin 64 15 c 34 7 c Decreased platelets 45 9 20 2.5 Decreased neutrophils 28 4.7 9 0.5 Chemistry Decreased estimated glomerular filtration rate (eGFR) 43 3.6 28 2.5 Decreased sodium 34 0.6 c 23 1 Decreased calcium 34 1.9 18 1.5 Increased aspartate aminotransferase (AST) 29 1.1 18 1 c Increased potassium 24 0.6 18 0.5 c Increased sodium 11 0 c 5 0 c"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"description_table":["
Table 7: Lutetium-177 Main Radiations
RadiationEnergy (keV)Iβ-%Iγ%
β-176.512.2
β-248.10.05
β-384.99.1
β-497.878.6
γ71.60.15
γ112.96.40
γ136.70.05
γ208.411.0
γ249.70.21
γ321.30.22
","
Table 8: Physical Decay Chart: Lutetium-177 Physical Half-life = 6.647 days
HoursFraction remaining
01.000
10.996
20.991
50.979
100.958
24 (1 day)0.901
48 (2 days)0.812
72 (3 days)0.731
120 (5 days)0.594
168 (7 days)0.482
336 (14 days)0.232
720 (30 days)0.044
1080 (45 days)0.009
"],"mechanism_of_action":["12.1 Mechanism of Action Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death."],"recent_major_changes":["Dosage and Administration, Radiation Dosimetry ( 2.6 ) 4/2026"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death. 12.2 Pharmacodynamics Lutetium Lu 177 vipivotide tetraxetan exposure-efficacy relationships and the time course of pharmacodynamic response have not been fully characterized. Cardiac Electrophysiology At the recommended dosage, PLUVICTO does not cause large mean increases (> 20 ms) in the QTc interval. 12.3 Pharmacokinetics Pharmacokinetics of lutetium Lu 177 vipivotide tetraxetan are expressed as geometric mean (geometric mean coefficient of variation) unless otherwise specified. The blood lutetium Lu 177 vipivotide tetraxetan area under the curve (AUC) is 52.3 ng.h/mL (31.4%) and the maximum blood concentration (C max ) is 6.58 ng/mL (43.5%) at the recommended dosage. Distribution Lutetium Lu 177 vipivotide tetraxetan volume of distribution is 123 L (78.1%). Within 2.5 hours after administration, lutetium Lu 177 vipivotide tetraxetan distributes in gastrointestinal tract, liver, lungs, kidneys, heart wall, bone marrow, and salivary glands. Vipivotide tetraxetan and non-radioactive lutetium vipivotide tetraxetan are 60% to 70% bound to human plasma proteins. Elimination The lutetium Lu 177 vipivotide tetraxetan terminal elimination half-life is 41.6 hours (68.8%) and the clearance (CL) is 2.04 L/h (31.5%). Metabolism Lutetium Lu 177 vipivotide tetraxetan does not undergo hepatic or renal metabolism. Excretion Lutetium Lu 177 vipivotide tetraxetan is primarily eliminated renally. Specific Populations Exposure (AUC) of lutetium Lu 177 vipivotide tetraxetan increased with decreasing creatinine clearance (CLcr). The effect of baseline CLcr < 54 mL/min on lutetium Lu 177 vipivotide tetraxetan pharmacokinetics has not been studied. Drug Interaction Studies In Vitro Studies CYP450 enzymes: Vipivotide tetraxetan is not a substrate of cytochrome P450 (CYP450) enzymes. Vipivotide tetraxetan did not induce CYP1A2, 2B6 or 3A4; and did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A in vitro. Transporters: Vipivotide tetraxetan is not a substrate of BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3 or OCT2. Vipivotide tetraxetan did not inhibit BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 or OCT2 in vitro."],"indications_and_usage":["1 INDICATIONS AND USAGE PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy. PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Risk From Radiation Exposure : Minimize radiation exposure during and after treatment with PLUVICTO consistent with institutional good radiation safety practices and patient treatment procedures. Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation. ( 5.1 ) Myelosuppression : Perform complete blood counts. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity. ( 2.4 , 5.2 ) Renal Toxicity : Advise patients to remain well hydrated and to urinate frequently. Perform kidney function laboratory tests. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity. ( 2.4 , 5.3 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception. ( 5.4 , 8.1 , 8.3 ) Infertility : PLUVICTO may cause temporary or permanent infertility. ( 5.5 , 8.3 ) 5.1 Risk From Radiation Exposure PLUVICTO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional good radiation safety practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home. Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation. Before the patient is released, inform patients about the necessary radioprotection precautions to follow to minimize radiation exposure to others [see Patient Counseling Information (17)] . After each administration of PLUVICTO, advise patients to: Limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days. Sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days. 5.2 Myelosuppression PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia. In the PSMAfore study, Grade 3 or 4 decreased hemoglobin (7%), decreased leukocytes (4.4%), decreased neutrophils (3.5%), and decreased platelets (2.7%) occurred in patients treated with PLUVICTO. One death occurred due to bone marrow failure during long-term follow-up in a patient who received PLUVICTO. In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets (9%), decreased leukocytes (7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO. Grade ≥ 3 pancytopenia occurred in 1.1% (which includes two fatal events) of patients treated with PLUVICTO. Two deaths (0.4%) occurred due to intracranial hemorrhage and subdural hematoma in association with thrombocytopenia, one death (0.2%) occurred due to sepsis and concurrent neutropenia, and one death (0.2%) occurred due to bone marrow failure. Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on the severity of myelosuppression [see Dosage and Administration (2.4)] . 5.3 Renal Toxicity PLUVICTO can cause severe renal toxicity. In the PSMAfore study, Grade 3 or 4 acute kidney injury (1.3%) occurred in patients treated with PLUVICTO. In the VISION study, Grade 3 or 4 acute kidney injury (3.4%) occurred in patients treated with PLUVICTO. Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform kidney function laboratory tests, including serum creatinine and calculated creatinine clearance (CLcr), before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on the severity of renal toxicity [see Dosage and Administration (2.4)] . 5.4 Embryo-Fetal Toxicity The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)] . No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from PLUVICTO, can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose [see Use in Specific Populations (8.1, 8.3)] . 5.5 Infertility PLUVICTO may cause infertility in males. The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility [see Use in Specific Populations (8.3)] ."],"clinical_studies_table":["
Table 9: Efficacy Results in PSMAfore
ARPI = androgen receptor pathway inhibitor; NE = Not estimable; NS = Not statistically significant aBy BICR per PCWG3-modified RECIST v1.1 criteria. bExcludes one patient in the PLUVICTO arm who was randomized after the data cut-off for the rPFS primary analysis. cBased on Kaplan-Meier estimate. dHazard ratio based on the stratified Cox PH model. eStratified log-rank test one-sided p-value. fResponses are based on soft tissue and bone lesion assessment.
PLUVICTOARPI
Radiographic progression-free survival (rPFS)aN = 233bN = 234
Events (progression or death), n (%)60 (26) 106 (45)
Median, months (95% CI)c9.3 (7, NE) 5.6 (4, 6)
Hazard ratio (95% CI)d0.41 (0.29, 0.56)
P-valuee< 0.0001
Overall survival (OS)N = 234 N = 234
Deaths, n (%) 142 (61) 157 (67)
Median, months (95% CI)c24.5 (19.5, 28.9) 23.1 (19.6, 25.5)
Hazard ratio (95% CI)d0.91 (0.72, 1.14)
P-valueeNS
Overall response rate (ORR)a,f
Patients with measurable disease at baseline N = 72 N = 72
ORR (CR + PR), n (%) (95% CI) 35 (49) (37, 61) 10 (14) (7, 24)
Complete response (CR), n (%) 15 (21) 2 (2.8)
Partial response (PR), n (%) 20 (28) 8 (11)
","
Table 10: Efficacy Results in VISION
aBased on Kaplan-Meier estimate. bHazard ratio based on the stratified Cox PH model. cStratified log-rank test two-sided p-value. dResponses are based on soft tissue and bone lesion assessment. eBy BICR per PCWG3-modified RECIST v1.1 criteria. fStratified Wald’s Chi-square test two-sided p-value.
PLUVICTO plus BSoCBSoC
Overall survival (OS)N = 551 N = 280
Deaths, n (%)343 (62) 187 (67)
Median, months (95% CI)a15.3 (14.2, 16.9) 11.3 (9.8, 13.5)
Hazard ratio (95% CI)b0.62 (0.52, 0.74)
P-valuec< 0.001
Overall response rate (ORR)d,e
Patients with measurable disease at baseline N = 184 N = 64
ORR (CR + PR), n (%) (95% CI) 91 (49) (42, 57) 1 (1.6) (0, 8)
Complete response (CR), n (%) 17 (9) 0 (0)
Partial response (PR), n (%) 74 (40) 1 (1.6)
P-valuef< 0.001
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and mutagenicity studies have not been conducted with lutetium Lu 177 vipivotide tetraxetan; however, radiation is a carcinogen and mutagen. No animal studies were conducted to determine the effects of lutetium Lu 177 vipivotide tetraxetan on fertility."],"adverse_reactions_table":["
Table 3: Adverse Reactions (≥ 10%) in Patients With PSMA-Positive mCRPC Who Received PLUVICTO in PSMAfore
Abbreviation: ARPI, androgen receptor pathway inhibitor. aIncludes multiple similar terms.
Adverse reactionsPLUVICTO (N = 227)ARPI (N = 232)
All Grades (%)Grades 3 or 4 (%)All Grades (%)Grades 3 or 4 (%)
Gastrointestinal disorders
Dry moutha61 0.9 2.6 0
Nausea32 0 12 0.4
Constipation22 0.4 14 0
Diarrhea 17 0 9 0.4
Vomiting11 0 4.7 0
General disorders
Fatiguea53 1.3 53 5
Metabolism and nutrition disorders
Decreased appetite 22 0 19 0.4
Musculoskeletal and connective tissue disorders
Arthralgia 20 0 23 0.4
Back pain 14 1.3 20 2.6
","
Table 4: Select Laboratory Abnormalities (≥ 10%) That Worsened From Baseline in Patients With PSMA-Positive mCRPC Who Received PLUVICTO or Change in ARPI (Between Arm Difference of ≥ 5% All Grades) in PSMAfore
Abbreviation: ARPI, androgen receptor pathway inhibitor. aThe denominator used to calculate the rate for each laboratory parameter was based on 226 patients with a baseline value and at least one post-treatment value. bThe denominator used to calculate the rate for each laboratory parameter varied from 231 to 232 based on the number of patients with a baseline value and at least one post-treatment value. cNo Grade 4 laboratory abnormalities worsening from baseline were reported.
Laboratory abnormalitiesPLUVICTOaARPIb
All Grades (%)Grades 3 or 4 (%)All Grades (%)Grades 3 or 4 (%)
Hematology
Decreased lymphocytes 78 27 57 12
Decreased hemoglobin 67 7c50 7c
Decreased neutrophils 38 3.5 18 1.3
Decreased platelets 30 2.7 11 1.7
Chemistry
Increased alkaline phosphatase 31 8 50 10c
Decreased estimated glomerular filtration rate (eGFR)23 0.9c22 3.5
Increased magnesium 19 0.9c28 0c
Decreased calcium 18 0.9 11 0.9
Decreased sodium 11 0c18 0c
Decreased potassium 6 0.9c18 2.6
","
Table 5: Adverse Reactions (≥ 10%) in Patients With PSMA-Positive mCRPC Who Received PLUVICTO Plus BSoC in VISION
Abbreviation: BSoC, best standard of care. aIncludes multiple similar terms.
Adverse reactionsPLUVICTO plus BSoC (N = 529)BSoC (N = 205)
All Grades (%)Grades 3 or 4 (%)All Grades (%)Grades 3 or 4 (%)
General disorders
Fatiguea48 7 29 2.4
Decreased appetite21 1.9 15 0.5
Weight decreased 11 0.4 10 0.5
Peripheral edemaa10 0.4 7 1
Gastrointestinal disorders
Dry moutha39 0 1 0
Nausea 36 1.3 17 0.5
Constipation 20 1.1 11 0.5
Vomitinga19 0.9 6 0.5
Diarrhea 19 0.8 2.9 0.5
Abdominal paina12 1.3 6 0.5
Musculoskeletal and connective tissue disorders
Back pain 24 3.6 15 3.9
Arthralgia 22 1.1 13 0.5
Bone pain 11 2.5 8 2.4
Renal and urinary disorders
Urinary tract infectiona12 3.8 1 0.5
","
Table 6: Select Laboratory Abnormalities (≥ 10%) That Worsened From Baseline in Patients With PSMA-Positive mCRPC Who Received PLUVICTO Plus BSoC (Between Arm Difference of ≥ 5% All Grades) in VISION
Abbreviation: BSoC, best standard of care. aThe denominator used to calculate the rate for each laboratory parameter varied from 506 to 529 based on the number of patients with a baseline value and at least one post-treatment value. bThe denominator used to calculate the rate for each laboratory parameter varied from 194 to 198 based on the number of patients with a baseline value and at least one post-treatment value. cNo Grade 4 laboratory abnormalities worsening from baseline were reported.
Laboratory abnormalitiesPLUVICTO plus BSoCaBSoCb
All Grades (%)Grades 3 or 4 (%)All Grades (%)Grades 3 or 4 (%)
Hematology
Decreased lymphocytes 85 47 51 18
Decreased hemoglobin 64 15c34 7c
Decreased platelets 45 9 20 2.5
Decreased neutrophils 28 4.7 9 0.5
Chemistry
Decreased estimated glomerular filtration rate (eGFR) 43 3.6 28 2.5
Decreased sodium 34 0.6c23 1
Decreased calcium 34 1.9 18 1.5
Increased aspartate aminotransferase (AST) 29 1.1 18 1c
Increased potassium 24 0.6 18 0.5c
Increased sodium 11 0c5 0c
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Risk From Radiation Exposure Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation. Before the patient is released, inform patients about the necessary radioprotection precautions to follow to minimize radiation exposure to others. After each administration of PLUVICTO, advise patients to: Limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days. Sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days [see Warnings and Precautions (5.1)] . Myelosuppression Advise patients to contact their healthcare provider for any signs or symptoms of myelosuppression, such as tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty to stop bleeding, or frequent infections with signs, such as fever, chills, sore throat or mouth ulcers [see Warnings and Precautions (5.2)] . Renal Toxicity Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Advise patients to contact their healthcare provider for any signs or symptoms of renal toxicity, such as passing urine less often than usual or passing much smaller amounts of urine than usual [see Warnings and Precautions (5.3)] . Embryo-Fetal Toxicity Advise males that PLUVICTO can cause fetal harm [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)] . Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose [see Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)] . Infertility Advise males of reproductive potential that PLUVICTO may cause temporary or permanent infertility [see Warnings and Precautions (5.5), Use in Specific Populations (8.3)] . Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936 ©2026 Novartis PLUVICTO ® is a registered trademark of Novartis AG and/or its affiliates. U.S. Patents 10398791; 10406240; 11318121; 12208102 T2026-11"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Select patients for treatment using LOCAMETZ ® or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors. ( 2.2 ) Recommended Dosage: Administer 7.4 GBq (200 mCi) every 6 weeks for 6 doses. ( 2.3 ) Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions. ( 2.4 ) 2.1 Important Safety Instructions PLUVICTO is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions (5.1)] . Use waterproof gloves and effective radiation shielding when handling PLUVICTO. Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals. 2.2 Patient Selection Select patients with previously treated mCRPC for treatment with PLUVICTO using LOCAMETZ or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors. Additional selection criteria were used in clinical studies [see Clinical Studies (14)] . 2.3 Recommended Dosage The recommended PLUVICTO dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks for 6 doses, or until disease progression, or unacceptable toxicity. 2.4 Dosage Modifications for Adverse Reactions Recommended dosage modifications of PLUVICTO for adverse reactions are provided in Table 1. Management of adverse reactions may require temporary dose interruption, dose reduction or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an adverse reaction persists for > 4 weeks, consider permanent discontinuation of PLUVICTO. The dose of PLUVICTO may be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose. If a patient has further adverse reactions that would require an additional dose reduction, treatment with PLUVICTO must be discontinued. Table 1: Recommended Dosage Modifications of PLUVICTO for Adverse Reactions Abbreviations: CLcr, creatinine clearance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal. Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE). Adverse reaction Severity Dosage modification Myelosuppression (Anemia, thrombocytopenia, leukopenia, or neutropenia) [see Warnings and Precautions (5.2)] Grade 2 Withhold PLUVICTO until improvement to Grade 1 or baseline. Grade ≥ 3 Withhold PLUVICTO until improvement to Grade 1 or baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Recurrent Grade ≥ 3 myelosuppression after one dose reduction Permanently discontinue PLUVICTO. Renal toxicity [see Warnings and Precautions (5.3)] Defined as: Confirmed serum creatinine increase (Grade ≥ 2) Confirmed CLcr < 30 mL/min; calculate using Cockcroft-Gault with actual body weight Withhold PLUVICTO until improvement. Defined as: Confirmed ≥ 40% increase from baseline serum creatinine and Confirmed > 40% decrease from baseline CLcr; calculate using Cockcroft-Gault with actual body weight Withhold PLUVICTO until improvement or return to baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Grade ≥ 3 renal toxicity Permanently discontinue PLUVICTO. Recurrent renal toxicity after one dose reduction Permanently discontinue PLUVICTO. Dry mouth [see Adverse Reactions (6.1)] Grade 2 Withhold PLUVICTO until improvement or return to baseline. Consider reducing PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Grade 3 Withhold PLUVICTO until improvement or return to baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Recurrent Grade 3 dry mouth after one dose reduction Permanently discontinue PLUVICTO. Gastrointestinal toxicity [see Adverse Reactions (6.1)] Grade ≥ 3 (not amenable to medical intervention) Withhold PLUVICTO until improvement to Grade 2 or baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Recurrent Grade ≥ 3 gastrointestinal toxicity after one dose reduction Permanently discontinue PLUVICTO. Fatigue [see Adverse Reactions (6.1)] Grade ≥ 3 Withhold PLUVICTO until improvement to Grade 2 or baseline. Electrolyte or metabolic abnormalities [see Adverse Reactions (6.1)] Grade ≥ 2 Withhold PLUVICTO until improvement to Grade 1 or baseline. Other non-hematologic toxicity [see Adverse Reactions (6.1)] Any unacceptable toxicity Permanently discontinue PLUVICTO. Any adverse reaction that requires treatment delay of > 4 weeks Permanently discontinue PLUVICTO. Any recurrent Grade 3 or 4 or persistent and intolerable Grade 2 adverse reaction after one dose reduction Permanently discontinue PLUVICTO. 2.5 Preparation and Administration Preparation Instructions Use aseptic technique and radiation shielding when handling or administering PLUVICTO, using tongs as needed to minimize radiation exposure. Inspect the product visually under a shielded screen for particulate matter and discoloration prior to administration. Discard the vial if particulates and/or discoloration are present. Do not inject the PLUVICTO solution directly into any other intravenous solution. Confirm the amount of radioactivity of PLUVICTO delivered to the patient with an appropriately calibrated dose calibrator prior to and after each PLUVICTO administration. Dispose of any unused medicinal product or waste material in accordance with local and federal laws. Administration Instructions Prior to administration, flush the intravenous catheter used exclusively for PLUVICTO administration with ≥ 10 mL of 0.9% Sodium Chloride Injection, USP to ensure patency and to minimize the risk of extravasation. Manage cases of extravasation as per institutional guidelines. The recommended dosage of PLUVICTO may be administered intravenously as an injection using the syringe method, as an infusion using the gravity method, or as an infusion using the peristaltic pump method. When using the gravity or peristaltic pump method, infuse PLUVICTO directly from its original container. Use the syringe method or the peristaltic pump method when administering a reduced dose of PLUVICTO following a dosage modification for an adverse reaction. When using the gravity method for a reduced dose, adjust the PLUVICTO dose before the administration to avoid the delivery of an incorrect volume of PLUVICTO. Intravenous Methods of Administration Instructions for the Syringe Method Withdraw an appropriate volume of PLUVICTO solution to deliver the desired radioactivity by using a disposable syringe fitted with a syringe shield and a disposable sterile needle that is 9 cm, 18 gauge (long needle). To aid the withdrawal of the solution, a filtered 2.5 cm, 20 gauge needle (short venting needle) can be used to reduce the resistance from the pressurized vial. Ensure that the short needle does not touch the PLUVICTO solution in the vial. Administer PLUVICTO to the patient by slow intravenous push within approximately 1 to 10 minutes (either with a syringe pump or manually without a syringe pump) via an intravenous catheter that is primed with 0.9% Sodium Chloride Injection, USP and that is used exclusively for PLUVICTO administration to the patient. If using a syringe pump, fit the syringe into the shielded pump and include a 3-way stopcock valve between the syringe and an intravenous catheter primed with 0.9% Sodium Chloride Injection, USP and used for PLUVICTO administration to the patient. When the desired PLUVICTO radioactivity has been delivered, stop the syringe pump and then change the position of the 3-way stopcock valve to flush the syringe with 25 mL of 0.9% Sodium Chloride Injection, USP. Restart the syringe pump. After the flush of the syringe has been completed, perform an intravenous flush of ≥ 10 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient. Instructions for the Gravity Method Insert a 2.5 cm, 20 gauge needle (short needle) into the PLUVICTO vial and connect via a catheter to 500 mL 0.9% Sodium Chloride Injection, USP (used to transport the PLUVICTO solution during the infusion). Ensure that the short needle does not touch the PLUVICTO solution in the vial and do not connect the short needle directly to the patient. Do not allow the 0.9% Sodium Chloride Injection, USP to flow into the PLUVICTO vial prior to the initiation of the PLUVICTO infusion and do not inject the PLUVICTO solution directly into the 0.9% Sodium Chloride Injection, USP. Insert a second needle that is 9 cm, 18 gauge (long needle) into the PLUVICTO vial, ensuring that the long needle touches and is secured to the bottom of the PLUVICTO vial during the entire infusion. Connect the long needle to the patient by an intravenous catheter that is primed with 0.9% Sodium Chloride Injection, USP and that is used exclusively for the PLUVICTO infusion into the patient. Use a clamp or an infusion pump to regulate the flow of the 0.9% Sodium Chloride Injection, USP via the short needle into the PLUVICTO vial (the 0.9% Sodium Chloride Injection, USP entering the vial through the short needle will carry the PLUVICTO solution from the vial to the patient via the intravenous catheter connected to the long needle within approximately 30 minutes). During the infusion, ensure that the level of solution in the PLUVICTO vial remains constant. Disconnect the vial from the long needle line and clamp the 0.9% Sodium Chloride Injection, USP line once the level of radioactivity is stable for at least five minutes. Follow the infusion with an intravenous flush of ≥ 10 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient. Instructions for the Peristaltic Pump Method Insert a filtered 2.5 cm, 20 gauge needle (short venting needle) into the PLUVICTO vial. Ensure that the short needle does not touch the PLUVICTO solution in the vial and do not connect the short needle directly to the patient or to the peristaltic pump. Insert a second needle that is 9 cm, 18 gauge (long needle) into the PLUVICTO vial, ensuring that the long needle touches and is secured to the bottom of the PLUVICTO vial during the entire infusion. Connect the long needle and a 0.9% Sodium Chloride Injection, USP to a 3-way stopcock valve via appropriate tubing. Connect the output of the 3-way stopcock valve to tubing installed on the input side of the peristaltic pump according to manufacturer’s instructions. Prime the line by opening the 3-way stopcock valve and pumping the PLUVICTO solution through the tubing until it reaches the exit of the valve. Prime the intravenous catheter which will be connected to the patient by opening the 3-way stopcock valve to the 0.9% Sodium Chloride Injection, USP and pumping the 0.9% Sodium Chloride Injection, USP until it exits the end of the catheter tubing. Connect the primed intravenous catheter to the patient and set the 3-way stopcock valve such that the PLUVICTO solution is in line with the peristaltic pump. Infuse an appropriate volume of PLUVICTO solution at approximately 25 mL/h to deliver the desired radioactivity. When the desired PLUVICTO radioactivity has been delivered, stop the peristaltic pump and then change the position of the 3-way stopcock valve so that the peristaltic pump is in line with the 0.9% Sodium Chloride Injection, USP. Restart the peristaltic pump and infuse an intravenous flush of ≥ 10 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient. 2.6 Radiation Dosimetry Dosimetry of lutetium Lu 177 vipivotide tetraxetan was collected in 29 patients in the VISION sub-study, in order to calculate whole body and organ radiation dosimetry. The mean and standard deviation (SD) of the estimated radiation absorbed doses to different organs for adults receiving PLUVICTO are shown in Table 2. The organs with the highest radiation absorbed doses are lacrimal glands, salivary glands, large intestine (left and right colon), kidneys, and urinary bladder wall. The maximum penetration of lutetium-177 in tissue is approximately 2 mm and the mean penetration is 0.67 mm. Table 2: Estimated Radiation Absorbed Dose a for PLUVICTO in VISION a Radiation absorbed dose estimates were derived using OLINDA v2.4 radiation dosimetry software, using measured time-activity data from patient imaging as input. Specific methods and software used for bone marrow and osteogenic cells dosimetry estimates are included below: * Estimated radiation absorbed dose based on activity measured in blood samples collected from patients, and dosimetry calculations using OLINDA v2.4. ** Estimated radiation absorbed dose based on activity measured in patient imaging (voxelized analysis of measured activity in bone marrow regions approximately 1 cm adjacent to bone metastasis activity within the vertebrae T8-L5) from 81 individual volume of interest (VOI) collected from 28 patients, and dosimetry calculations using Hermia Voxel Dosimetry v3.1.0. Absorbed dose per unit activity (Gy/GBq) N = 29 Calculated absorbed dose for 7.4 GBq administration (Gy) Calculated absorbed dose for 6 x 7.4 GBq (44.4 GBq cumulative activity) (Gy) Organ Mean SD Mean SD Mean SD Adrenals 0.033 0.026 0.25 0.19 1.5 1.1 Brain 0.0069 0.0051 0.051 0.038 0.30 0.23 Esophagus 0.025 0.026 0.18 0.19 1.1 1.2 Eyes 0.022 0.025 0.16 0.18 0.98 1.1 Gallbladder wall 0.028 0.026 0.21 0.19 1.3 1.2 Heart wall 0.17 0.12 1.3 0.88 7.8 5.3 Kidneys 0.42 0.19 3.1 1.4 19 8.4 Lacrimal glands 2.1 0.48 15 3.6 92 21 Left colon 0.58 0.14 4.3 1.0 26 6.1 Liver 0.093 0.050 0.69 0.37 4.1 2.2 Lungs 0.11 0.11 0.78 0.83 4.7 5.0 Osteogenic cells: -blood-based* 0.036 0.029 0.26 0.21 1.6 1.3 -image-based** 0.048 0.038 0.36 0.28 2.1 1.7 Pancreas 0.027 0.026 0.20 0.19 1.2 1.2 Prostate 0.027 0.026 0.20 0.19 1.2 1.2 Rectum 0.56 0.14 4.1 1.1 25 6.3 Red marrow: -blood-based* 0.035 0.020 0.26 0.15 1.5 0.91 -image-based** 0.055 0.046 0.41 0.34 2.5 2.1 Right colon 0.32 0.079 2.4 0.58 14 3.5 Salivary glands 0.63 0.37 4.6 2.7 28 16 Small intestine 0.071 0.031 0.52 0.23 3.1 1.4 Spleen 0.061 0.028 0.45 0.21 2.7 1.2 Stomach wall 0.025 0.026 0.19 0.19 1.1 1.2 Testes 0.023 0.025 0.17 0.19 1.0 1.1 Thymus 0.024 0.026 0.18 0.19 1.1 1.2 Thyroid 0.26 0.37 1.9 2.8 11 17 Total body 0.037 0.027 0.28 0.20 1.7 1.2 Urinary bladder wall 0.32 0.025 2.4 0.19 14 1.1"],"spl_product_data_elements":["PLUVICTO lutetium Lu 177 vipivotide tetraxetan ACETIC ACID SODIUM ACETATE GENTISIC ACID SODIUM ASCORBATE PENTETIC ACID WATER LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan as a clear and colorless to slightly yellow solution in a single-dose vial. Injection: 1,000 MBq/mL (27 mCi/mL) in a single-dose vial. ( 3 )"],"recent_major_changes_table":["
Dosage and Administration, Radiation Dosimetry (2.6)4/2026
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)] . There are no available data on PLUVICTO use in pregnant females. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radioactive emissions, including those from PLUVICTO, can cause fetal harm. 8.2 Lactation Risk Summary The safety and efficacy of PLUVICTO have not been established in females. There are no data on the presence of lutetium Lu 177 vipivotide tetraxetan in human milk or its effects on the breastfed child or on milk production. 8.3 Females and Males of Reproductive Potential Contraception Males Advise males with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)] . Infertility The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility. 8.4 Pediatric Use The safety and effectiveness of PLUVICTO in pediatric patients have not been established. 8.5 Geriatric Use Of the 227 patients who received at least one dose of PLUVICTO in the PSMAfore study, 177 patients (78%) were 65 years of age or older and 83 patients (37%) were 75 years of age or older. No overall differences in effectiveness were observed between patients ≥ 75 years of age and younger patients. Serious adverse reactions occurred in 20% of patients ≥ 75 years of age and in 20% of younger patients. Grade ≥ 3 adverse reactions occurred in 39% of patients ≥ 75 years of age and in 34% of younger patients. Of the 529 patients who received at least one dose of PLUVICTO plus BSoC in the VISION study, 387 patients (73%) were 65 years of age or older and 143 patients (27%) were 75 years of age or older. No overall differences in effectiveness were observed between patients ≥ 75 years of age and younger patients. Serious adverse reactions occurred in 41% of patients ≥ 75 years of age and in 35% of younger patients. Grade ≥ 3 adverse reactions occurred in 56% of patients ≥ 75 years of age and in 53% of younger patients. 8.6 Renal Impairment Exposure of lutetium Lu 177 vipivotide tetraxetan is expected to increase with the degree of renal impairment [see Clinical Pharmacology (12.3)] . No dose adjustment is recommended for patients with mild (baseline CLcr 60 to 89 mL/min by Cockcroft-Gault) to moderate (CLcr 30 to 59 mL/min) renal impairment; however, patients with mild to moderate renal impairment may be at greater risk of toxicity. Frequently monitor renal function and adverse reactions in patients with mild to moderate renal impairment [see Dosage and Administration (2.4)] . The pharmacokinetics and safety of PLUVICTO have not been studied in patients with severe (CLcr 15 to 29 mL/min) renal impairment or end-stage renal disease."],"dosage_and_administration_table":["
Table 1: Recommended Dosage Modifications of PLUVICTO for Adverse Reactions
Abbreviations: CLcr, creatinine clearance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal. Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE).
Adverse reactionSeverityDosage modification
Myelosuppression (Anemia, thrombocytopenia, leukopenia, or neutropenia) [see Warnings and Precautions (5.2)]Grade 2Withhold PLUVICTO until improvement to Grade 1 or baseline.
Grade ≥ 3Withhold PLUVICTO until improvement to Grade 1 or baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade ≥ 3 myelosuppression after one dose reductionPermanently discontinue PLUVICTO.
Renal toxicity [see Warnings and Precautions (5.3)]Defined as: Confirmed serum creatinine increase (Grade ≥ 2)Confirmed CLcr < 30 mL/min; calculate using Cockcroft-Gault with actual body weightWithhold PLUVICTO until improvement.
Defined as: Confirmed ≥ 40% increase from baseline serum creatinine andConfirmed > 40% decrease from baseline CLcr; calculate using Cockcroft-Gault with actual body weightWithhold PLUVICTO until improvement or return to baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Grade ≥ 3 renal toxicity Permanently discontinue PLUVICTO.
Recurrent renal toxicity after one dose reductionPermanently discontinue PLUVICTO.
Dry mouth [see Adverse Reactions (6.1)]Grade 2Withhold PLUVICTO until improvement or return to baseline. Consider reducing PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Grade 3Withhold PLUVICTO until improvement or return to baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade 3 dry mouth after one dose reductionPermanently discontinue PLUVICTO.
Gastrointestinal toxicity [see Adverse Reactions (6.1)]Grade ≥ 3 (not amenable to medical intervention)Withhold PLUVICTO until improvement to Grade 2 or baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade ≥ 3 gastrointestinal toxicity after one dose reductionPermanently discontinue PLUVICTO.
Fatigue [see Adverse Reactions (6.1)]Grade ≥ 3Withhold PLUVICTO until improvement to Grade 2 or baseline.
Electrolyte or metabolic abnormalities [see Adverse Reactions (6.1)]Grade ≥ 2Withhold PLUVICTO until improvement to Grade 1 or baseline.
Other non-hematologic toxicity [see Adverse Reactions (6.1)]Any unacceptable toxicityPermanently discontinue PLUVICTO.
Any adverse reaction that requires treatment delay of > 4 weeksPermanently discontinue PLUVICTO.
Any recurrent Grade 3 or 4 or persistent and intolerable Grade 2 adverse reaction after one dose reductionPermanently discontinue PLUVICTO.
","
Table 2: Estimated Radiation Absorbed Dosea for PLUVICTO in VISION
aRadiation absorbed dose estimates were derived using OLINDA v2.4 radiation dosimetry software, using measured time-activity data from patient imaging as input. Specific methods and software used for bone marrow and osteogenic cells dosimetry estimates are included below: *Estimated radiation absorbed dose based on activity measured in blood samples collected from patients, and dosimetry calculations using OLINDA v2.4. **Estimated radiation absorbed dose based on activity measured in patient imaging (voxelized analysis of measured activity in bone marrow regions approximately 1 cm adjacent to bone metastasis activity within the vertebrae T8-L5) from 81 individual volume of interest (VOI) collected from 28 patients, and dosimetry calculations using Hermia Voxel Dosimetry v3.1.0.
Absorbed dose per unit activity (Gy/GBq) N = 29Calculated absorbed dose for 7.4 GBq administration (Gy) Calculated absorbed dose for 6 x 7.4 GBq (44.4 GBq cumulative activity) (Gy)
OrganMeanSDMeanSDMeanSD
Adrenals0.0330.0260.250.191.51.1
Brain0.00690.00510.0510.0380.300.23
Esophagus0.0250.0260.180.191.11.2
Eyes0.0220.0250.160.180.981.1
Gallbladder wall0.0280.0260.210.191.31.2
Heart wall0.170.121.30.887.85.3
Kidneys0.420.193.11.4198.4
Lacrimal glands2.10.48153.69221
Left colon0.580.144.31.0266.1
Liver0.0930.0500.690.374.12.2
Lungs0.110.110.780.834.75.0
Osteogenic cells:
-blood-based*0.0360.0290.260.211.61.3
-image-based**0.0480.0380.360.282.11.7
Pancreas0.0270.0260.200.191.21.2
Prostate0.0270.0260.200.191.21.2
Rectum0.560.144.11.1256.3
Red marrow:
-blood-based*0.0350.0200.260.151.50.91
-image-based**0.0550.0460.410.342.52.1
Right colon0.320.0792.40.58143.5
Salivary glands0.630.374.62.72816
Small intestine0.0710.0310.520.233.11.4
Spleen0.0610.0280.450.212.71.2
Stomach wall0.0250.0260.190.191.11.2
Testes0.0230.0250.170.191.01.1
Thymus0.0240.0260.180.191.11.2
Thyroid0.260.371.92.81117
Total body0.0370.0270.280.201.71.2
Urinary bladder wall0.320.0252.40.19141.1
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL PLUVICTO ® 1,000 MBq/mL (27 mCi/mL) lutetium Lu 177 vipivotide tetraxetan injection Intravenous use Single-dose vial Sterile NDC# 0078-1217-61 Rx Only NOVARTIS PRINCIPAL DISPLAY PANEL PLUVICTO® 1,000 MBq/mL (27 mCi/mL) lutetium Lu 177 vipivotide tetraxetan injection Intravenous use Single-dose vial Sterile NDC# 0078-1217-61 Rx Only NOVARTIS"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and mutagenicity studies have not been conducted with lutetium Lu 177 vipivotide tetraxetan; however, radiation is a carcinogen and mutagen. No animal studies were conducted to determine the effects of lutetium Lu 177 vipivotide tetraxetan on fertility."]},"tags":[{"label":"Radioligand Therapeutic Agent [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"},{"label":"metastatic castration-resistant prostate cancer (mCRPC)","category":"indication"},{"label":"metastatic castration-resistant prostate cancer (mCRPC)","category":"indication"},{"label":"Novartis","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Decreased lymphocytes","drugRate":"83%","severity":"serious","_validated":true},{"effect":"Decreased hemoglobin","drugRate":"65%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"49%","severity":"common","_validated":true},{"effect":"Dry mouth","drugRate":"46%","severity":"common","_validated":true},{"effect":"Decreased platelets","drugRate":"40%","severity":"common","_validated":true},{"effect":"Decreased estimated glomerular filtration rate","drugRate":"37%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"35%","severity":"common","_validated":true},{"effect":"Decreased neutrophils","drugRate":"31%","severity":"common","_validated":true},{"effect":"Decreased calcium","drugRate":"29%","severity":"common","_validated":true},{"effect":"Decreased sodium","drugRate":"27%","severity":"common","_validated":true},{"effect":"Increased aspartate aminotransferase","drugRate":"26%","severity":"common","_validated":true},{"effect":"Increased alkaline phosphatase","drugRate":"24%","severity":"common","_validated":true},{"effect":"Arthralgia","drugRate":"22%","severity":"common","_validated":true},{"effect":"Decreased appetite","drugRate":"21%","severity":"common","_validated":true},{"effect":"Increased potassium","drugRate":"21%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"21%","severity":"common","_validated":true},{"effect":"Back pain","drugRate":"21%","severity":"common","_validated":true},{"effect":"Anemia","drugRate":"18%","severity":"common","_validated":true},{"effect":"Urinary tract infection","drugRate":"18%","severity":"common","_validated":true},{"effect":"Hemorrhage","drugRate":"13%","severity":"common","_validated":true},{"effect":"Sepsis","drugRate":"13%","severity":"common","_validated":true},{"effect":"COVID-19 pneumonia","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Musculoskeletal pain","drugRate":"reported","severity":"unknown"},{"effect":"Pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Spinal cord compression","drugRate":"reported","severity":"unknown"},{"effect":"Pulmonary embolism","drugRate":"reported","severity":"unknown"}],"contraindications":[],"specialPopulations":{"Pregnancy":"The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm. There are no available data on PLUVICTO use in pregnant females. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radioactive emissions, including those from PLUVICTO, can cause fetal harm.","Geriatric use":"Of the 227 patients who received at least one dose of PLUVICTO in the PSMAfore study, 177 patients (78%) were 65 years of age or older and 83 patients (37%) were 75 years of age or older. No overall differences in effectiveness were observed between patients ≥ 75 years of age and younger patients. Serious adverse reactions occurred in 20% of patients ≥ 75 years of age and in 20% of younger patients. Grade ≥ 3 adverse reactions occurred in 39% of patients ≥ 75 years of age and in 30% of younger patients.","Paediatric use":"The safety and effectiveness of PLUVICTO in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TETRAXETAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:34:16.429518+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Tetraxetan","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:34:23.086052+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:34:21.731946+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TETRAXETAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:34:22.044499+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:13.656784+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:13.656817+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:13.656822+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Mucin-5AC binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:34:23.085981+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301586/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:34:22.741726+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA215833","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:13.656825+00:00"}},"allNames":"pluvicto","offLabel":[],"synonyms":["Pluvicto","LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN"],"timeline":[{"date":"20250328","type":"positive","source":"OpenFDA","milestone":"FDA approval (Novartis)"}],"aiSummary":"Pluvicto (tetraxetan) is a radioligand therapeutic agent developed by Novartis for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a small molecule with a half-life of 41.6 hours and has been FDA-approved since 2025. Pluvicto targets the PSMA protein, which is highly expressed in prostate cancer cells, allowing for targeted therapy. The commercial status of Pluvicto is patented, and it is not yet available as a generic product. Key safety considerations include its potential to cause bone marrow suppression and gastrointestinal toxicity.","approvals":[{"date":"20250328","orphan":false,"company":"NOVARTIS","regulator":"FDA"}],"brandName":"Pluvicto","ecosystem":[],"mechanism":{"moaClass":"Radioligand Activity [MoA]","modality":"Small Molecule","drugClass":"Radioligand Therapeutic Agent [EPC]","explanation":"Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death.","oneSentence":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells.","technicalDetail":"Pluvicto is a small molecule radioligand therapeutic agent that selectively binds to the prostate-specific membrane antigen (PSMA) through a high-affinity interaction, allowing for targeted delivery of the alpha-particle emitting radionuclide actinium-225 (225Ac) to prostate cancer cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/DOTA_(chelator)","title":"DOTA (chelator)","extract":"DOTA is an organic compound with the formula (CH2CH2NCH2CO2H)4. The molecule consists of a central 12-membered tetraaza ring. DOTA is used as a complexing agent, especially for lanthanide ions. Its complexes have medical applications as contrast agents and cancer treatments."},"commercial":{"launchDate":"2025","revenueYear":2025,"_launchSource":"OpenFDA (20250328, NOVARTIS)","annualRevenue":386,"revenueSource":"SEC 8-K Novartis (2024-10-29)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:46.559724","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"TETRAXETAN\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"TETRAXETAN\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=tetraxetan","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tetraxetan","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/DOTA_(chelator)","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:23:56.429639","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:34:26.469481+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"tetraxetan","indications":{"approved":[{"name":"metastatic castration-resistant prostate cancer (mCRPC)","source":"OpenFDA Label","regulator":"FDA"},{"name":"metastatic castration-resistant prostate cancer (mCRPC)","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"startDate":"2021-06-15","conditions":["Prostatic Neoplasms"],"enrollment":469,"completionDate":"2026-09-30"},{"nctId":"NCT07290270","phase":"","title":"Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-04","conditions":["Metastatic Prostate Cancer"],"enrollment":170,"completionDate":"2029-08-31"},{"nctId":"NCT06526299","phase":"PHASE2","title":"Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-04-29","conditions":["Metastatic Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":51,"completionDate":"2027-12-31"},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"enrollment":63,"completionDate":"2027-01-13"},{"nctId":"NCT05939414","phase":"PHASE3","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-12","conditions":["Oligometastatic Prostate Cancer (OMPC)"],"enrollment":450,"completionDate":"2031-10-03"},{"nctId":"NCT07484269","phase":"","title":"PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-08-01","conditions":["Metastatic Prostate Cancer"],"enrollment":753,"completionDate":"2031-07-31"},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":["Prostate Cancer"],"enrollment":1247,"completionDate":"2025-03-14"},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":40,"completionDate":"2028-01-27"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":["Prostate Carcinoma","Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8"],"enrollment":90,"completionDate":"2028-12-31"},{"nctId":"NCT06004661","phase":"PHASE2","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-04","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"enrollment":20,"completionDate":"2026-06-17"},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":474,"completionDate":"2034-10-11"},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":["Prostatic Neoplasm"],"enrollment":49,"completionDate":"2026-12-23"},{"nctId":"NCT07047118","phase":"PHASE2","title":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-03","conditions":["Prostatic Cancer, Castration-Resistant"],"enrollment":130,"completionDate":"2028-11-04"},{"nctId":"NCT06964958","phase":"PHASE2","title":"177LuPSMA in Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2025-07-31","conditions":["Renal Cell Carcinoma","Advanced Clear Cell Renal Cell Carcinoma","Kidney Cancer"],"enrollment":24,"completionDate":"2028-12-01"},{"nctId":"NCT07093801","phase":"","title":"Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-30","conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":300,"completionDate":"2029-03-30"},{"nctId":"NCT07226986","phase":"PHASE1,PHASE2","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-05","conditions":["PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy"],"enrollment":123,"completionDate":"2029-09-13"},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":7,"completionDate":"2029-04-09"},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"enrollment":62,"completionDate":"2026-06-30"},{"nctId":"NCT06099093","phase":"PHASE4","title":"Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-04-01","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Metastatic Castration-resistant Prostate Carcinoma"],"enrollment":30,"completionDate":"2026-12-01"},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":15,"completionDate":"2027-12-30"},{"nctId":"NCT07219147","phase":"PHASE1","title":"177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-05","conditions":["Metastatic Castration-Resistant Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2028-07-26"},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":69,"completionDate":"2027-12-31"},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"enrollment":106,"completionDate":"2028-11-24"},{"nctId":"NCT06517719","phase":"","title":"Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":500,"completionDate":"2028-02-01"},{"nctId":"NCT06514521","phase":"","title":"Post Marketing Study on Pluvicto in Korea","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-18","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":278,"completionDate":"2028-05-31"},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":["Oligometastatic Prostate Adenocarcinoma","Recurrent Prostate Adenocarcinoma"],"enrollment":107,"completionDate":"2031-10-31"},{"nctId":"NCT05682443","phase":"PHASE1,PHASE2","title":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoC4, Inc.","startDate":"2023-12-11","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":148,"completionDate":"2027-06-30"},{"nctId":"NCT07054346","phase":"PHASE1","title":"Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617","status":"RECRUITING","sponsor":"Thomas Hope","startDate":"2025-07-08","conditions":["Prostate Cancer","Prostate Cancer (Diagnosis)","High-risk Prostate Cancer","Localized Prostate Carcinoma","Very High Risk Prostate Carcinoma"],"enrollment":45,"completionDate":"2028-04-30"},{"nctId":"NCT07200830","phase":"PHASE3","title":"Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial","status":"NOT_YET_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-10-08","conditions":["Metastatic Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":1524,"completionDate":"2034-09-09"},{"nctId":"NCT07197580","phase":"PHASE3","title":"Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","status":"NOT_YET_RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-11-15","conditions":["ccRCC","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Renal Cell Cancer Metastatic","Renal Cell Cancer, Recurrent","Clear Cell Renal Cell Cancer (ccRCC)"],"enrollment":40,"completionDate":"2029-02-28"},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":["Prostate Cancer Metastatic"],"enrollment":3360,"completionDate":"2032-03"},{"nctId":"NCT06516510","phase":"EARLY_PHASE1","title":"A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Blue Earth Therapeutics Ltd","startDate":"2024-10-31","conditions":["Metastatic Prostate Cancer"],"enrollment":17,"completionDate":"2025-08-15"},{"nctId":"NCT05113537","phase":"PHASE1,PHASE2","title":"Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Vadim S Koshkin","startDate":"2022-07-08","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8","Metastatic Castration-resistant Prostate Carcinoma","Metastatic Castration-resistant Prostate Cancer"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":236,"completionDate":"2029-12-31"},{"nctId":"NCT06549465","phase":"PHASE2","title":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","status":"RECRUITING","sponsor":"Convergent Therapeutics","startDate":"2024-08-06","conditions":["PSMA PET-Positive Castration-Resistant Prostate Cancer"],"enrollment":60,"completionDate":"2027-04"},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":430,"completionDate":"2030-12"},{"nctId":"NCT06303713","phase":"PHASE1","title":"LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-22","conditions":["Prostate Cancer","Metastatic Prostate Cancer","Metastatic Castration-resistant Prostate Cancer"],"enrollment":37,"completionDate":"2026-07-19"},{"nctId":"NCT05803941","phase":"PHASE4","title":"Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-14","conditions":["Prostate Cancer"],"enrollment":700,"completionDate":"2033-07-21"},{"nctId":"NCT06199453","phase":"PHASE2","title":"The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial","status":"WITHDRAWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2024-01","conditions":["Adenoid Cystic Carcinoma"],"enrollment":0,"completionDate":"2027-11"},{"nctId":"NCT06449781","phase":"PHASE2","title":"177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2025-01-09","conditions":["Prostate Cancer"],"enrollment":200,"completionDate":"2030-11"},{"nctId":"NCT02658968","phase":"PHASE1","title":"Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)","status":"COMPLETED","sponsor":"Nordic Nanovector","startDate":"2017-03-02","conditions":["Relapsed, Diffuse Large B-cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":18,"completionDate":"2021-07-10"},{"nctId":"NCT02592707","phase":"PHASE1,PHASE2","title":"Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":["Neuroendocrine Tumors"],"enrollment":40,"completionDate":"2022-02-22"},{"nctId":"NCT03773133","phase":"PHASE1,PHASE2","title":"Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)","status":"TERMINATED","sponsor":"Ipsen","startDate":"2019-05-14","conditions":["Small Cell Lung Cancer and Breast Cancer"],"enrollment":9,"completionDate":"2019-10-10"},{"nctId":"NCT01510561","phase":"PHASE1","title":"A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":["Metastatic Pancreatic Adenocarcinoma","Pancreatic Cancer","Metastatic Pancreatic Cancer"],"enrollment":0,"completionDate":"2015-09"},{"nctId":"NCT01101581","phase":"PHASE1,PHASE2","title":"Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2010-05","conditions":["Non Hodgkin's Lymphoma","NHL","Aggressive NHL","Diffuse Large B-cell Lymphoma"],"enrollment":0,"completionDate":"2017-03"},{"nctId":"NCT01956812","phase":"PHASE3","title":"Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-12","conditions":["Metastatic Pancreatic Cancer","Pancreatic Cancer"],"enrollment":334,"completionDate":"2016-11"},{"nctId":"NCT02657447","phase":"PHASE1","title":"Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)","status":"WITHDRAWN","sponsor":"Nordic Nanovector","startDate":"2017-12-19","conditions":["Non-Hodgkin Lymphoma"],"enrollment":0,"completionDate":"2020-09"},{"nctId":"NCT01147393","phase":"PHASE1,PHASE2","title":"Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2010-10","conditions":["Follicular Lymphoma"],"enrollment":4,"completionDate":"2015-07-31"},{"nctId":"NCT02844530","phase":"PHASE2","title":"Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL","status":"WITHDRAWN","sponsor":"Nantes University Hospital","startDate":"","conditions":["CD22+ Relapsed/Refractory B-ALL"],"enrollment":0,"completionDate":"2017-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT04689828"],"administration":{"route":"Intravenous","formulation":"Solution","formulations":[{"form":"SOLUTION","route":"INTRAVENOUS","productName":""}]},"crossReferences":{"UNII":"G6UF363ECX","RXCUI":"2597057,2597060","SPL_ID":"14908037-2892-4d98-a053-253ce35afb1a","chemblId":"CHEMBL3301586"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Novartis","relationship":"Original Developer"}],"pharmacokinetics":{"source":"OpenFDA Label","halfLife":"41.6 hours"},"publicationCount":86,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:46.587237+00","applicationNumber":"NDA215833","biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[{"date":"2026 Feb 26","pmid":"41746558","title":"Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.","journal":"EJNMMI radiopharmacy and chemistry"},{"date":"2026 Feb 26","pmid":"41741857","title":"Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective.","journal":"AAPS PharmSciTech"},{"date":"2026 Feb 11","pmid":"41623163","title":"Site-Specific Asymmetric Coordination Engineering in Defective Metal-Organic Frameworks Stabilizes Cu(I) Active Sites for Selective CO(2)-to-Methanol Photocatalysis.","journal":"Journal of the American Chemical Society"},{"date":"2026 Jan 14","pmid":"41598623","title":"Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium ((177)Lu)Vipivotide Tetraxetan, and Abiraterone.","journal":"Journal of clinical medicine"},{"date":"2026 Jan 12","pmid":"41595153","title":"PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions.","journal":"Cancers"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"2025","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"NOVARTIS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:34:26.469481+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}